Mcag.Pk

MCAG.PK exhibits a highly leveraged capital structure, with total liabilities of $3.72 million and total equity of -$2.85 million, resulting in a negative debt-to-equity ratio of -0.46. The company's liquidity position is weak, as evidenced by a current ratio of 0.02, indicating that it holds only $0.02 in current assets for every $1 of current liabilities. The negative net cash position after subtracting total debt further exacerbates liquidity concerns.

Profitability metrics reveal significant underperformance. The company reported a net loss of $431,160 and an operating loss of $471,780 in the latest period. Return on equity (ROE) of 15.13% appears high in absolute terms but is misleading due to the negative equity base. Return on assets (ROA) of -49.36% indicates that the company is generating substantial losses relative to its asset base. These figures fall well below the typical performance of firms in the Investment Holding Companies industry.

The company's revenue concentration and geographic exposure are not disclosed in the available data, but the negative equity and high leverage suggest a lack of diversification in its investment portfolio. The absence of segment-specific data limits the ability to assess the risk profile of individual holdings.

Growth trajectory is negative, with no clear path to profitability or asset appreciation. The company reported a free cash flow of -$431,160 and an operating cash flow of -$742,000, indicating a lack of cash generation. Without a reversal in operating performance, the company is unlikely to meet the growth expectations of the broader industry.

Risk factors include a high probability of insolvency due to negative equity and weak liquidity. The risk assessment indicates a medium liquidity risk and a low dilution risk, but the negative net cash position after subtracting total debt is a red flag. The company has not disclosed any recent capital-raising activities or dilution events, but the negative equity position suggests a potential need for equity infusions in the near term.

Recent events, including filings and transcripts, are not available in the provided data. The company's financial disclosures suggest a lack of transparency and a need for further due diligence to assess its long-term viability.